These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32383192)

  • 1. Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Slawik HR; Bückner U; Otremba B; Sauer A; Zahn MO; Wetzel N; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2020 Aug; 38(3):344-352. PubMed ID: 32383192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
    Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Laribi K; Poulain S; Willems L; Merabet F; Herbaux C; Roos-Weil D; Laribi de Materre I; Roussel X; Nudel M; Tricot S; Dupuis J; Le Calloch R; Bareau B; Leblond V
    Br J Haematol; 2024 Jun; 204(6):2233-2236. PubMed ID: 38504454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
    Treon SP; Hunter Z; Barnagan AR
    Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.
    Sakurai M; Mori T; Uchiyama H; Ago H; Iwato K; Eto T; Iwasaki H; Kawata T; Takamatsu H; Yamasaki S; Takanashi M; Ichinohe T; Atsuta Y; Suzuki R
    Ann Hematol; 2020 Jul; 99(7):1635-1642. PubMed ID: 32424672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
    Izutsu K; Kato H; Sekiguchi N; Fujisaki T; Kawakita T; Obara N; Matsue K; Nishimoto M; Hatayama T; Inagaki M; Fujikawa E
    Int J Hematol; 2024 Jul; 120(1):80-90. PubMed ID: 38597986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
    Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
    Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Mohm J; Rauh J; Harde J; Kaiser-Osterhues A; Jänicke M; Marschner N;
    Eur J Haematol; 2019 Nov; 103(5):460-471. PubMed ID: 31314918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM).
    Chiappella A; Ciochetto C; Orsucci L; Vitolo U
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):149-51. PubMed ID: 21454219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
    Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
    Buske C; Sadullah S; Kastritis E; Tedeschi A; García-Sanz R; Bolkun L; Leleu X; Willenbacher W; Hájek R; Minnema MC; Cheng M; Bilotti E; Graef T; Dimopoulos MA;
    Lancet Haematol; 2018 Jul; 5(7):e299-e309. PubMed ID: 29958569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
    Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
    Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.